콘텐츠로 건너뛰기
Merck
모든 사진(3)

Key Documents

P6402

Sigma-Aldrich

Perphenazine

동의어(들):

4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C21H26ClN3OS
CAS Number:
Molecular Weight:
403.97
EC Number:
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.77

형태

powder

Quality Level

주관자

Schering Plough

저장 온도

2-8°C

SMILES string

ClC(C=C1)=CC2=C1SC3=CC=CC=C3N2CCCN4CCN(CCO)CC4

InChI

1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

InChI key

RGCVKNLCSQQDEP-UHFFFAOYSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

Perphenazine is an antipsychotic drug used in treating schizophrenia. It modulates antioxidant levels and helps in the management of oxidative injury in schizophrenia. However, it is less effective than the clozapine drug group in improving response to oxidative injury.

생화학적/생리학적 작용

D2 dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro.

특징 및 장점

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

픽토그램

Exclamation mark

신호어

Warning

유해 및 위험 성명서

Hazard Classifications

Acute Tox. 4 Oral - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

J Nordenberg et al.
Biochemical pharmacology, 58(8), 1229-1236 (1999-09-16)
Some of the psychotropic agents widely used for the amelioration of anxiety, depression, and psychosis also show an effect at the cellular proliferation level. Surprisingly little research, however, has been directed to the antitumoral potential of these drugs, alone or
Donald E Addington et al.
The Journal of clinical psychiatry, 72(1), 75-80 (2010-09-28)
According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the
Angela M Koranek et al.
Schizophrenia research, 137(1-3), 137-140 (2012-03-01)
Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine. This study evaluated the effect
Frank B Yoon et al.
Statistics in medicine, 30(16), 1917-1932 (2011-05-04)
In clinical trials multiple outcomes are often used to assess treatment interventions. This paper presents an evaluation of likelihood-based methods for jointly testing treatment effects in clinical trials with multiple continuous outcomes. Specifically, we compare the power of joint tests
Eric Hermes et al.
Journal of psychopharmacology (Oxford, England), 26(9), 1194-1200 (2012-04-21)
There is evidence to suggest that clozapine is underutilized in treatment-refractory schizophrenia. Data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), a multi-phase, randomized comparative effectiveness trial for schizophrenia, were used to identify factors associated with choosing randomization to

문서

Sigma-Aldrich presents an article about how proliferatively active cells require both a source of carbon and of nitrogen for the synthesis of macromolecules. Although a large proportion of tumor cells utilize aerobic glycolysis and shunt metabolites away from mitochondrial oxidative phosphorylation, many tumor cells exhibit increased mitochondrial activity.

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.